Enzalutamide - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (7)Carriers (1)Transporters (1)

Targets (1)Enzymes (7)Carriers (1)Transporters (1)Biointeractions (11)

Identification

Name

Enzalutamide

Accession Number

DB08899 (DB05094)

Type

Small Molecule

Groups

Approved

Description

Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Not Available

External IDs

MDV 3100 / MDV-3100 / MDV3100

Product Ingredients

Not Available

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Xtandi	Capsule	40 mg	Oral	Astellas Pharma Inc	2013-06-07	Not applicable	Canada
Xtandi	Capsule	40 mg	Oral	Astellas Pharma Europe Bv	2013-06-21	Not applicable	EU
Xtandi	Capsule	40 mg/1	Oral	Astellas Pharma Inc	2012-08-31	Not applicable	US

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

93T0T9GKNU

CAS number

915087-33-1

Weight

Average: 464.436
Monoisotopic: 464.093009286

Chemical Formula

C₂₁H₁₆F₄N₄O₂S

InChI Key

WXCXUHSOUPDCQV-UHFFFAOYSA-N

InChI

InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)

IUPAC Name

4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide

SMILES

CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F

Pharmacology

Indication

Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

Structured Indications

Metastatic Castration Resistant Prostate Cancer

Pharmacodynamics

Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52.

Mechanism of action

Enzalutamide is a competitive androgen receptor inhibitor that effects multiple stages of the signalling pathway. It is able to inhibit androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with DNA. As a result, proliferation of prostate cancer cells decreases which ultimately leads to apoptosis and decreased tumour volume.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Androgen receptor	Protein	yes	inhibitor	Human	P10275	details

Absorption

The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Enzalutamide also accumulates. Food does not affect its absorption. Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours); Cmax, steady state, enzalutamide = 16.6 μg/mL; Cmax, steady state, N-desmethyl enzalutamide = 12.7 μg/mL; Time to steady state, daily dosing = 28 days;

Volume of distribution

Apparent volume of distribution (Vd/F), single oral dose = 110 L

Protein binding

Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins.

Metabolism

Enzalutamide is hepatically metabolized, primarily by CYP2C8 and CYP3A4. The enzyme that converts enzalutamide to its active metabolite, N-desmethyl enzalutamide, is CYP2C8. The activity of N-desmethyl-enzalutamide is similar to that of the parent compound.

Route of elimination

Enzalutamide is primarily eliminated by hepatic metabolism. 71% of the dose is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).

Half life

The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.

Clearance

Apparent clearance (CL/F), single oral dose = 0.56 L/h (range of 0.33 - 1.02 L/h)

Toxicity

The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Enzalutamide.	Investigational
19-norandrostenedione	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide.	Experimental, Illicit
5-androstenedione	The serum concentration of 5-androstenedione can be decreased when it is combined with Enzalutamide.	Experimental, Illicit
Abiraterone	The serum concentration of Abiraterone can be decreased when it is combined with Enzalutamide.	Approved
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Enzalutamide.	Approved
Acenocoumarol	The serum concentration of Acenocoumarol can be decreased when it is combined with Enzalutamide.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Enzalutamide.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Enzalutamide.	Approved, Vet Approved
Adinazolam	The serum concentration of Adinazolam can be decreased when it is combined with Enzalutamide.	Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Enzalutamide.	Approved
Albendazole	The serum concentration of Albendazole can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Alclometasone	The serum concentration of Alclometasone can be decreased when it is combined with Enzalutamide.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Enzalutamide.	Experimental
Alfentanil	The serum concentration of Alfentanil can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Aliskiren	The serum concentration of Aliskiren can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Allylestrenol	The serum concentration of Allylestrenol can be decreased when it is combined with Enzalutamide.	Approved
Almotriptan	The serum concentration of Almotriptan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Alogliptin	The serum concentration of Alogliptin can be decreased when it is combined with Enzalutamide.	Approved
Alosetron	The serum concentration of Alosetron can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Alprazolam	The serum concentration of Alprazolam can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ambroxol	The serum concentration of Ambroxol can be decreased when it is combined with Enzalutamide.	Approved
Amcinonide	The serum concentration of Amcinonide can be decreased when it is combined with Enzalutamide.	Approved
Aminophenazone	The serum concentration of Aminophenazone can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Enzalutamide.	Approved
Amiodarone	The serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be decreased when it is combined with Enzalutamide.	Approved
Amlodipine	The serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide.	Approved
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Enzalutamide.	Approved
Amprenavir	The serum concentration of Amprenavir can be decreased when it is combined with Enzalutamide.	Approved
Androstenedione	The serum concentration of 4-Androstenedione can be decreased when it is combined with Enzalutamide.	Experimental, Illicit
Anecortave	The serum concentration of Anecortave can be decreased when it is combined with Enzalutamide.	Investigational
Antipyrine	The serum concentration of Antipyrine can be decreased when it is combined with Enzalutamide.	Approved
Apixaban	The serum concentration of Apixaban can be decreased when it is combined with Enzalutamide.	Approved
Apremilast	The serum concentration of Apremilast can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Aprepitant	The serum concentration of Aprepitant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Argatroban	The serum concentration of Argatroban can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Arsenic trioxide	The serum concentration of Arsenic trioxide can be increased when it is combined with Enzalutamide.	Approved, Investigational
Artemether	The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.	Approved
Asenapine	The serum concentration of Asenapine can be decreased when it is combined with Enzalutamide.	Approved
Astemizole	The serum concentration of Astemizole can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Atazanavir	The serum concentration of Atazanavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be increased when it is combined with Enzalutamide.	Approved
Atomoxetine	The metabolism of Enzalutamide can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide.	Approved
Avanafil	The serum concentration of Avanafil can be decreased when it is combined with Enzalutamide.	Approved
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Azelastine	The serum concentration of Azelastine can be decreased when it is combined with Enzalutamide.	Approved
Azithromycin	The serum concentration of Azithromycin can be decreased when it is combined with Enzalutamide.	Approved
Banoxantrone	The serum concentration of Banoxantrone can be decreased when it is combined with Enzalutamide.	Investigational
Beclomethasone dipropionate	The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bedaquiline	The serum concentration of Bedaquiline can be decreased when it is combined with Enzalutamide.	Approved
Benzphetamine	The serum concentration of Benzphetamine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Benzyl alcohol	The serum concentration of Benzyl alcohol can be decreased when it is combined with Enzalutamide.	Approved
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Enzalutamide.	Approved, Vet Approved
Bexarotene	The serum concentration of Enzalutamide can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bezafibrate	The serum concentration of Bezafibrate can be decreased when it is combined with Enzalutamide.	Approved
Bicalutamide	The serum concentration of Bicalutamide can be decreased when it is combined with Enzalutamide.	Approved
Bisoprolol	The serum concentration of Bisoprolol can be decreased when it is combined with Enzalutamide.	Approved
Boceprevir	The serum concentration of Boceprevir can be decreased when it is combined with Enzalutamide.	Withdrawn
Bortezomib	The serum concentration of Bortezomib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bosentan	The serum concentration of Enzalutamide can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Enzalutamide.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide.	Approved
Brexpiprazole	The serum concentration of Brexpiprazole can be decreased when it is combined with Enzalutamide.	Approved
Brinzolamide	The serum concentration of Brinzolamide can be decreased when it is combined with Enzalutamide.	Approved
Bromazepam	The serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Bromocriptine	The serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Brompheniramine	The serum concentration of Brompheniramine can be decreased when it is combined with Enzalutamide.	Approved
Budesonide	The serum concentration of Budesonide can be decreased when it is combined with Enzalutamide.	Approved
Bupivacaine	The serum concentration of Bupivacaine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Buprenorphine	The serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The serum concentration of Bupropion can be decreased when it is combined with Enzalutamide.	Approved
Buspirone	The serum concentration of Buspirone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Busulfan	The serum concentration of Busulfan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cabazitaxel	The serum concentration of Cabazitaxel can be decreased when it is combined with Enzalutamide.	Approved
Cabergoline	The serum concentration of Cabergoline can be decreased when it is combined with Enzalutamide.	Approved
Cabozantinib	The serum concentration of Cabozantinib can be decreased when it is combined with Enzalutamide.	Approved
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Enzalutamide.	Approved
Calcitriol	The serum concentration of Calcitriol can be decreased when it is combined with Enzalutamide.	Approved, Nutraceutical
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Enzalutamide.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.	Approved
Cannabidiol	The serum concentration of Cannabidiol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Carbamazepine	The serum concentration of Enzalutamide can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The serum concentration of Carbinoxamine can be decreased when it is combined with Enzalutamide.	Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Enzalutamide.	Approved
Cariprazine	The serum concentration of Cariprazine can be decreased when it is combined with Enzalutamide.	Approved
Carvedilol	The serum concentration of Carvedilol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Celecoxib	The serum concentration of Celecoxib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Celiprolol	The serum concentration of Celiprolol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cephalexin	The serum concentration of Cephalexin can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Ceritinib	The serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Enzalutamide.	Withdrawn
Cevimeline	The serum concentration of Cevimeline can be decreased when it is combined with Enzalutamide.	Approved
Chenodeoxycholic acid	The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Enzalutamide.	Approved
Chlordiazepoxide	The serum concentration of Chlordiazepoxide can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Chloroquine	The serum concentration of Chloroquine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Chlorphenamine	The serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide.	Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Chlorzoxazone	The serum concentration of Chlorzoxazone can be decreased when it is combined with Enzalutamide.	Approved
Cholecalciferol	The serum concentration of Cholecalciferol can be decreased when it is combined with Enzalutamide.	Approved, Nutraceutical
Ciclesonide	The serum concentration of Ciclesonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cilostazol	The serum concentration of Cilostazol can be decreased when it is combined with Enzalutamide.	Approved
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Enzalutamide.	Approved
Cinacalcet	The serum concentration of Cinacalcet can be decreased when it is combined with Enzalutamide.	Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Cisapride	The serum concentration of Cisapride can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Enzalutamide.	Approved
Citalopram	The serum concentration of Citalopram can be decreased when it is combined with Enzalutamide.	Approved
Clarithromycin	The serum concentration of Clarithromycin can be decreased when it is combined with Enzalutamide.	Approved
Clemastine	The metabolism of Enzalutamide can be decreased when combined with Clemastine.	Approved
Clindamycin	The serum concentration of Clindamycin can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clobetasol	The serum concentration of Clobetasol can be decreased when it is combined with Enzalutamide.	Investigational
Clobetasol propionate	The serum concentration of Clobetasol propionate can be decreased when it is combined with Enzalutamide.	Approved
Clocortolone	The serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide.	Approved
Clofazimine	The serum concentration of Clofazimine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Clofibrate	The serum concentration of Clofibrate can be decreased when it is combined with Enzalutamide.	Approved
clomethiazole	The serum concentration of clomethiazole can be decreased when it is combined with Enzalutamide.	Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Enzalutamide.	Approved, Investigational
Clomipramine	The serum concentration of Clomipramine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Clonazepam	The serum concentration of Clonazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Enzalutamide.	Approved
Clopidogrel	The serum concentration of Enzalutamide can be increased when it is combined with Clopidogrel.	Approved, Nutraceutical
Clorazepate	The serum concentration of Clorazepate can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clotiazepam	The serum concentration of Clotiazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clotrimazole	The metabolism of Enzalutamide can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Clozapine can be decreased when it is combined with Enzalutamide.	Approved
Cobicistat	The serum concentration of Enzalutamide can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Enzalutamide.	Approved
Cocaine	The serum concentration of Cocaine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Codeine	The serum concentration of Codeine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be decreased when it is combined with Enzalutamide.	Approved
Conivaptan	The serum concentration of Enzalutamide can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Enzalutamide.	Approved
Cortisone acetate	The serum concentration of Cortisone acetate can be decreased when it is combined with Enzalutamide.	Approved
Crizotinib	The serum concentration of Crizotinib can be decreased when it is combined with Enzalutamide.	Approved
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.	Approved
Cyclophosphamide	The serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cyclosporine	The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Cytarabine	The serum concentration of Cytarabine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide.	Approved
Dabrafenib	The serum concentration of Enzalutamide can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Daclatasvir can be decreased when it is combined with Enzalutamide.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Enzalutamide.	Approved
Dantrolene	The serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide.	Approved
Dapsone	The serum concentration of Dapsone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Darifenacin	The serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Darunavir	The serum concentration of Darunavir can be decreased when it is combined with Enzalutamide.	Approved
Dasabuvir	The serum concentration of Dasabuvir can be decreased when it is combined with Enzalutamide.	Approved
Dasatinib	The serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be decreased when it is combined with Enzalutamide.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Enzalutamide.	Approved
Deferasirox	The serum concentration of Enzalutamide can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Enzalutamide.	Approved
Desoximetasone	The serum concentration of Desoximetasone can be decreased when it is combined with Enzalutamide.	Approved
Desoxycorticosterone acetate	The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Enzalutamide.	Approved
Desoxycorticosterone Pivalate	The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Enzalutamide.	Experimental, Vet Approved
Desvenlafaxine	The serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide.	Approved
Dexamethasone	The serum concentration of Enzalutamide can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Enzalutamide.	Vet Approved
Dextromethorphan	The serum concentration of Dextromethorphan can be decreased when it is combined with Enzalutamide.	Approved
Dextropropoxyphene	The serum concentration of Dextropropoxyphene can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Withdrawn
Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Vet Approved
Diclofenac	The serum concentration of Diclofenac can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Enzalutamide.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Enzalutamide.	Approved
Diflorasone	The serum concentration of Diflorasone can be decreased when it is combined with Enzalutamide.	Approved
Difluocortolone	The serum concentration of Difluocortolone can be decreased when it is combined with Enzalutamide.	Approved
Difluprednate	The serum concentration of Difluprednate can be decreased when it is combined with Enzalutamide.	Approved
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide.	Approved
Digoxin	The serum concentration of Digoxin can be decreased when it is combined with Enzalutamide.	Approved
Dihydrocodeine	The serum concentration of Dihydrocodeine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Dihydroergotamine	The serum concentration of Dihydroergotamine can be decreased when it is combined with Enzalutamide.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Enzalutamide.	Illicit
Diltiazem	The serum concentration of Diltiazem can be decreased when it is combined with Enzalutamide.	Approved
Dipyridamole	The serum concentration of Dipyridamole can be increased when it is combined with Enzalutamide.	Approved
Disopyramide	The serum concentration of Disopyramide can be decreased when it is combined with Enzalutamide.	Approved
Disulfiram	The serum concentration of Disulfiram can be decreased when it is combined with Enzalutamide.	Approved
Docetaxel	The serum concentration of Docetaxel can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be decreased when it is combined with Enzalutamide.	Approved
Dolasetron	The serum concentration of Dolasetron can be decreased when it is combined with Enzalutamide.	Approved
Domperidone	The serum concentration of Domperidone can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Donepezil	The serum concentration of Donepezil can be decreased when it is combined with Enzalutamide.	Approved
Dorzolamide	The serum concentration of Dorzolamide can be decreased when it is combined with Enzalutamide.	Approved
Doxepin	The serum concentration of Doxepin can be decreased when it is combined with Enzalutamide.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Doxycycline	The metabolism of Enzalutamide can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Dronedarone	The serum concentration of Dronedarone can be decreased when it is combined with Enzalutamide.	Approved
Dutasteride	The serum concentration of Dutasteride can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Enzalutamide.	Approved
Efavirenz	The serum concentration of Enzalutamide can be decreased when it is combined with Efavirenz.	Approved, Investigational
Eletriptan	The serum concentration of Eletriptan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be decreased when it is combined with Enzalutamide.	Approved
Elvitegravir	The serum concentration of Elvitegravir can be decreased when it is combined with Enzalutamide.	Approved
Enalapril	The serum concentration of Enalapril can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be decreased when it is combined with Enzalutamide.	Approved
Equilenin	The serum concentration of Equilenin can be decreased when it is combined with Enzalutamide.	Experimental
Equilin	The serum concentration of Equilin can be decreased when it is combined with Enzalutamide.	Approved
Ergocalciferol	The serum concentration of Ergocalciferol can be decreased when it is combined with Enzalutamide.	Approved, Nutraceutical
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.	Approved
Ergonovine	The serum concentration of Ergonovine can be decreased when it is combined with Enzalutamide.	Approved
Ergotamine	The serum concentration of Ergotamine can be decreased when it is combined with Enzalutamide.	Approved
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Erythromycin	The serum concentration of Erythromycin can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Escitalopram	The serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Enzalutamide can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esomeprazole	The serum concentration of Esomeprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Estazolam	The serum concentration of Estazolam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Estradiol valerate/Dienogest	The serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Enzalutamide.	Approved
Estramustine	The serum concentration of Estramustine can be decreased when it is combined with Enzalutamide.	Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Enzalutamide.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be decreased when it is combined with Enzalutamide.	Approved
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Enzalutamide.	Approved
Eszopiclone	The serum concentration of Eszopiclone can be decreased when it is combined with Enzalutamide.	Approved
Ethanol	The serum concentration of Ethanol can be decreased when it is combined with Enzalutamide.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enzalutamide.	Approved
Ethosuximide	The serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide.	Approved
Ethylmorphine	The serum concentration of Ethylmorphine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Enzalutamide.	Approved
Etoricoxib	The serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Etravirine	The serum concentration of Enzalutamide can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be decreased when it is combined with Enzalutamide.	Approved
Exemestane	The serum concentration of Exemestane can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Enzalutamide.	Approved
Famciclovir	The serum concentration of Famciclovir can be decreased when it is combined with Enzalutamide.	Approved
Felbamate	The serum concentration of Felbamate can be decreased when it is combined with Enzalutamide.	Approved
Felodipine	The serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fenofibrate	The serum concentration of Fenofibrate can be decreased when it is combined with Enzalutamide.	Approved
Fentanyl	The serum concentration of Fentanyl can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Enzalutamide.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Enzalutamide.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Enzalutamide.	Approved
Finasteride	The serum concentration of Finasteride can be decreased when it is combined with Enzalutamide.	Approved
Fingolimod	The serum concentration of Fingolimod can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Flibanserin	The serum concentration of Flibanserin can be decreased when it is combined with Enzalutamide.	Approved
fluasterone	The serum concentration of fluasterone can be decreased when it is combined with Enzalutamide.	Investigational
Fluconazole	The metabolism of Enzalutamide can be decreased when combined with Fluconazole.	Approved
Fludrocortisone	The serum concentration of Fludrocortisone can be decreased when it is combined with Enzalutamide.	Approved
Flumethasone	The serum concentration of Flumethasone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Flunisolide	The serum concentration of Flunisolide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Flunitrazepam	The serum concentration of Flunitrazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Fluocinolone Acetonide	The serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Fluocinonide	The serum concentration of Fluocinonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fluocortolone	The serum concentration of Fluocortolone can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Fluorometholone	The serum concentration of Fluorometholone can be decreased when it is combined with Enzalutamide.	Approved
Fluoxetine	The serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Fluprednidene	The serum concentration of Fluprednidene can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Fluprednisolone	The serum concentration of Fluprednisolone can be decreased when it is combined with Enzalutamide.	Approved
Flurandrenolide	The serum concentration of Flurandrenolide can be decreased when it is combined with Enzalutamide.	Approved
Flurazepam	The serum concentration of Flurazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Flutamide	The serum concentration of Flutamide can be decreased when it is combined with Enzalutamide.	Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be decreased when it is combined with Enzalutamide.	Approved
Fluticasone propionate	The serum concentration of Fluticasone Propionate can be decreased when it is combined with Enzalutamide.	Approved
Fluvastatin	The serum concentration of Fluvastatin can be decreased when it is combined with Enzalutamide.	Approved
Fluvoxamine	The metabolism of Enzalutamide can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formestane	The serum concentration of Formestane can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Fosamprenavir	The serum concentration of Fosamprenavir can be decreased when it is combined with Enzalutamide.	Approved
Fosaprepitant	The serum concentration of Enzalutamide can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Enzalutamide can be decreased when it is combined with Fosphenytoin.	Approved
Fulvestrant	The serum concentration of Fulvestrant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fusidic Acid	The serum concentration of Enzalutamide can be increased when it is combined with Fusidic Acid.	Approved
Galantamine	The serum concentration of Galantamine can be decreased when it is combined with Enzalutamide.	Approved
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Enzalutamide.	Approved
Gemfibrozil	The serum concentration of Enzalutamide can be increased when it is combined with Gemfibrozil.	Approved
Glipizide	The serum concentration of Glipizide can be decreased when it is combined with Enzalutamide.	Approved
Glyburide	The serum concentration of Glyburide can be decreased when it is combined with Enzalutamide.	Approved
Granisetron	The serum concentration of Granisetron can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Enzalutamide.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Enzalutamide.	Withdrawn
Guanfacine	The serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Halofantrine	The serum concentration of Halofantrine can be decreased when it is combined with Enzalutamide.	Approved
Haloperidol	The serum concentration of Haloperidol can be decreased when it is combined with Enzalutamide.	Approved
Halothane	The serum concentration of Halothane can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
HE3286	The serum concentration of HE3286 can be decreased when it is combined with Enzalutamide.	Investigational
Hexobarbital	The serum concentration of Hexobarbital can be decreased when it is combined with Enzalutamide.	Approved
Histamine	The serum concentration of Histamine Phosphate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Hydrocodone	The serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Hydromorphone	The serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Hydroxyprogesterone caproate	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Enzalutamide.	Approved
Ibrutinib	The serum concentration of Ibrutinib can be decreased when it is combined with Enzalutamide.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Enzalutamide.	Approved
Idelalisib	The serum concentration of Enzalutamide can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The serum concentration of Ifosfamide can be decreased when it is combined with Enzalutamide.	Approved
Iloperidone	The serum concentration of Iloperidone can be decreased when it is combined with Enzalutamide.	Approved
Imatinib	The serum concentration of Imatinib can be decreased when it is combined with Enzalutamide.	Approved
Imipramine	The serum concentration of Imipramine can be decreased when it is combined with Enzalutamide.	Approved
Imiquimod	The serum concentration of Imiquimod can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Enzalutamide.	Approved
Indapamide	The serum concentration of Indapamide can be decreased when it is combined with Enzalutamide.	Approved
Indinavir	The serum concentration of Indinavir can be decreased when it is combined with Enzalutamide.	Approved
Indomethacin	The serum concentration of Indomethacin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Ipratropium bromide	The serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide.	Approved
Irbesartan	The metabolism of Enzalutamide can be decreased when combined with Irbesartan.	Approved, Investigational
Irinotecan	The serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Enzalutamide resulting in a loss in efficacy.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Enzalutamide resulting in a loss in efficacy.	Approved, Investigational
Isosorbide Dinitrate	The serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Enzalutamide.	Approved
Isosorbide Mononitrate	The serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Enzalutamide.	Approved
Isradipine	The serum concentration of Isradipine can be decreased when it is combined with Enzalutamide.	Approved
Istaroxime	The serum concentration of Istaroxime can be decreased when it is combined with Enzalutamide.	Investigational
Itraconazole	The serum concentration of Itraconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be decreased when it is combined with Enzalutamide.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be decreased when it is combined with Enzalutamide.	Approved
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Ixabepilone	The serum concentration of Ixabepilone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ixazomib	The serum concentration of Ixazomib can be decreased when it is combined with Enzalutamide.	Approved
Ketamine	The serum concentration of Ketamine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Enzalutamide.	Approved
Ketobemidone	The serum concentration of Ketobemidone can be decreased when it is combined with Enzalutamide.	Approved
Ketoconazole	The serum concentration of Ketoconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Enzalutamide.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Enzalutamide.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lapatinib	The serum concentration of Lapatinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Laquinimod	The serum concentration of Laquinimod can be decreased when it is combined with Enzalutamide.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Enzalutamide.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Enzalutamide.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be decreased when it is combined with Enzalutamide.	Approved
Lercanidipine	The serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Letrozole	The serum concentration of Letrozole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Enzalutamide.	Approved, Investigational
Levobupivacaine	The serum concentration of Levobupivacaine can be decreased when it is combined with Enzalutamide.	Approved
Levocetirizine	The serum concentration of Levocetirizine can be decreased when it is combined with Enzalutamide.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Levomethadyl Acetate	The serum concentration of Levomethadyl Acetate can be decreased when it is combined with Enzalutamide.	Approved
Levomilnacipran	The serum concentration of Levomilnacipran can be decreased when it is combined with Enzalutamide.	Approved
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Levothyroxine	The serum concentration of Levothyroxine can be decreased when it is combined with Enzalutamide.	Approved
Lidocaine	The serum concentration of Lidocaine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide.	Approved
Lisuride	The serum concentration of Lisuride can be decreased when it is combined with Enzalutamide.	Approved
Lomitapide	The serum concentration of Lomitapide can be decreased when it is combined with Enzalutamide.	Approved
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Enzalutamide.	Approved
Lopinavir	The serum concentration of Enzalutamide can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Loratadine can be decreased when it is combined with Enzalutamide.	Approved
Lorcaserin	The serum concentration of Lorcaserin can be decreased when it is combined with Enzalutamide.	Approved
Losartan	The serum concentration of Losartan can be decreased when it is combined with Enzalutamide.	Approved
Lovastatin	The serum concentration of Lovastatin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Luliconazole	The serum concentration of Enzalutamide can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Enzalutamide can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The serum concentration of Lumefantrine can be decreased when it is combined with Enzalutamide.	Approved
Lurasidone	The serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide.	Approved
Macitentan	The serum concentration of Macitentan can be decreased when it is combined with Enzalutamide.	Approved
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Enzalutamide.	Approved, Investigational
Maraviroc	The serum concentration of Maraviroc can be decreased when it is combined with Enzalutamide.	Approved, Investigational
ME-609	The serum concentration of ME-609 can be decreased when it is combined with Enzalutamide.	Investigational
Mebendazole	The serum concentration of Mebendazole can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Medroxyprogesterone acetate	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Medrysone	The serum concentration of Medrysone can be decreased when it is combined with Enzalutamide.	Approved
Mefloquine	The serum concentration of Mefloquine can be decreased when it is combined with Enzalutamide.	Approved
Melengestrol	The serum concentration of Melengestrol can be decreased when it is combined with Enzalutamide.	Vet Approved
Meloxicam	The serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Methadone	The serum concentration of Methadone can be decreased when it is combined with Enzalutamide.	Approved
Methaqualone	The serum concentration of Methaqualone can be decreased when it is combined with Enzalutamide.	Illicit, Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Enzalutamide.	Approved
Methoxsalen	The serum concentration of Methoxsalen can be decreased when it is combined with Enzalutamide.	Approved
Methoxyflurane	The serum concentration of Methoxyflurane can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Methyltestosterone	The serum concentration of Methyltestosterone can be decreased when it is combined with Enzalutamide.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Enzalutamide.	Approved, Investigational
Metronidazole	The serum concentration of Metronidazole can be decreased when it is combined with Enzalutamide.	Approved
Mexiletine	The serum concentration of Mexiletine can be decreased when it is combined with Enzalutamide.	Approved
Mianserin	The serum concentration of Mianserin can be decreased when it is combined with Enzalutamide.	Approved
Mibefradil	The serum concentration of Mibefradil can be decreased when it is combined with Enzalutamide.	Withdrawn
Miconazole	The serum concentration of Miconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Mifepristone	The serum concentration of Mifepristone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Enzalutamide.	Approved
Mirtazapine	The serum concentration of Mirtazapine can be decreased when it is combined with Enzalutamide.	Approved
Mitotane	The serum concentration of Enzalutamide can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Enzalutamide.	Approved, Investigational
Modafinil	The serum concentration of Enzalutamide can be decreased when it is combined with Modafinil.	Approved, Investigational
Mometasone	The serum concentration of Mometasone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Montelukast	The serum concentration of Montelukast can be decreased when it is combined with Enzalutamide.	Approved
Morphine	The serum concentration of Morphine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Enzalutamide.	Approved
Nafcillin	The serum concentration of Enzalutamide can be decreased when it is combined with Nafcillin.	Approved
Naloxegol	The serum concentration of Naloxegol can be decreased when it is combined with Enzalutamide.	Approved
Naloxone	The serum concentration of Naloxone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Nateglinide	The serum concentration of Nateglinide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
NCX 1022	The serum concentration of NCX 1022 can be decreased when it is combined with Enzalutamide.	Investigational
Nefazodone	The serum concentration of Nefazodone can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Nelfinavir	The serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide.	Approved
Netupitant	The serum concentration of Netupitant can be decreased when it is combined with Enzalutamide.	Approved
Nevirapine	The serum concentration of Enzalutamide can be decreased when it is combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Nicardipine can be decreased when it is combined with Enzalutamide.	Approved
Nicotine	The serum concentration of Nicotine can be decreased when it is combined with Enzalutamide.	Approved
Nifedipine	The serum concentration of Nifedipine can be decreased when it is combined with Enzalutamide.	Approved
Nilotinib	The serum concentration of Nilotinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nilvadipine	The serum concentration of Nilvadipine can be decreased when it is combined with Enzalutamide.	Approved
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Enzalutamide.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Enzalutamide.	Approved
Nisoldipine	The serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide.	Approved
Nitrazepam	The serum concentration of Nitrazepam can be decreased when it is combined with Enzalutamide.	Approved
Nitrendipine	The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Enzalutamide.	Approved
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Enzalutamide.	Approved
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Enzalutamide.	Approved
Nortriptyline	The serum concentration of Nortriptyline can be decreased when it is combined with Enzalutamide.	Approved
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Enzalutamide.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be decreased when it is combined with Enzalutamide.	Approved
Oleoyl-estrone	The serum concentration of Oleoyl estrone can be decreased when it is combined with Enzalutamide.	Investigational
Olopatadine	The serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Enzalutamide.	Approved
Omeprazole	The serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Ondansetron	The serum concentration of Ondansetron can be decreased when it is combined with Enzalutamide.	Approved
Orphenadrine	The serum concentration of Orphenadrine can be decreased when it is combined with Enzalutamide.	Approved
Osimertinib	The serum concentration of Osimertinib can be decreased when it is combined with Enzalutamide.	Approved
Ospemifene	The serum concentration of Ospemifene can be decreased when it is combined with Enzalutamide.	Approved
Oxazepam	The serum concentration of Oxazepam can be decreased when it is combined with Enzalutamide.	Approved
Oxybutynin	The serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Oxycodone	The serum concentration of Oxycodone can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Oxymorphone	The serum concentration of Oxymorphone can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Paclitaxel	The serum concentration of Paclitaxel can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Palbociclib	The serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide.	Approved
Palonosetron	The serum concentration of Palonosetron can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Panobinostat	The serum concentration of Panobinostat can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pantoprazole	The serum concentration of Pantoprazole can be decreased when it is combined with Enzalutamide.	Approved
Paramethadione	The serum concentration of Paramethadione can be decreased when it is combined with Enzalutamide.	Approved
Paramethasone	The serum concentration of Paramethasone can be decreased when it is combined with Enzalutamide.	Approved
Parecoxib	The serum concentration of Parecoxib can be decreased when it is combined with Enzalutamide.	Approved
Paricalcitol	The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Paritaprevir	The serum concentration of Paritaprevir can be decreased when it is combined with Enzalutamide.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Enzalutamide.	Approved
Pentamidine	The serum concentration of Pentamidine can be decreased when it is combined with Enzalutamide.	Approved
Pentobarbital	The serum concentration of Enzalutamide can be decreased when it is combined with Pentobarbital.	Approved, Vet Approved
Perampanel	The serum concentration of Perampanel can be decreased when it is combined with Enzalutamide.	Approved
Pergolide	The serum concentration of Pergolide can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved, Withdrawn
Perhexiline	The serum concentration of Perhexiline can be decreased when it is combined with Enzalutamide.	Approved
Permethrin	The serum concentration of Permethrin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Perphenazine	The serum concentration of Perphenazine can be decreased when it is combined with Enzalutamide.	Approved
Pethidine	The serum concentration of Pethidine can be decreased when it is combined with Enzalutamide.	Approved
Phenacetin	The serum concentration of Phenacetin can be decreased when it is combined with Enzalutamide.	Withdrawn
Phenobarbital	The serum concentration of Enzalutamide can be decreased when it is combined with Phenobarbital.	Approved
Phenoxybenzamine	The serum concentration of Phenoxybenzamine can be decreased when it is combined with Enzalutamide.	Approved
Phenprocoumon	The serum concentration of Phenprocoumon can be decreased when it is combined with Enzalutamide.	Approved
Phenytoin	The serum concentration of Enzalutamide can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pilocarpine	The serum concentration of Pilocarpine can be decreased when it is combined with Enzalutamide.	Approved
Pimecrolimus	The serum concentration of Pimecrolimus can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be decreased when it is combined with Enzalutamide.	Approved
Pinacidil	The serum concentration of Pinacidil can be decreased when it is combined with Enzalutamide.	Withdrawn
Pioglitazone	The serum concentration of Pioglitazone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pipotiazine	The serum concentration of Pipotiazine can be decreased when it is combined with Enzalutamide.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Enzalutamide.	Approved
Podofilox	The serum concentration of Podofilox can be decreased when it is combined with Enzalutamide.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.	Approved
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Enzalutamide.	Approved
Posaconazole	The serum concentration of Posaconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Prasterone	The serum concentration of Prasterone can be decreased when it is combined with Enzalutamide.	Approved, Nutraceutical
Prasterone sulfate	The serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Enzalutamide.	Investigational
Prasugrel	The serum concentration of Prasugrel can be decreased when it is combined with Enzalutamide.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide.	Approved
Prazepam	The serum concentration of Prazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Praziquantel	The serum concentration of Praziquantel can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Prazosin	The serum concentration of Prazosin can be increased when it is combined with Enzalutamide.	Approved
Prednicarbate	The serum concentration of Prednicarbate can be decreased when it is combined with Enzalutamide.	Approved
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Pregnenolone	The serum concentration of Pregnenolone can be decreased when it is combined with Enzalutamide.	Experimental
Primaquine	The serum concentration of Primaquine can be decreased when it is combined with Enzalutamide.	Approved
Primidone	The serum concentration of Enzalutamide can be decreased when it is combined with Primidone.	Approved, Vet Approved
Prochlorperazine	The serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Proguanil	The serum concentration of Proguanil can be decreased when it is combined with Enzalutamide.	Approved
Promazine	The serum concentration of Promazine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Propafenone	The serum concentration of Propafenone can be decreased when it is combined with Enzalutamide.	Approved
Propofol	The serum concentration of Propofol can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Enzalutamide.	Approved
Pyrazinamide	The serum concentration of Pyrazinamide can be decreased when it is combined with Enzalutamide.	Approved
Quazepam	The serum concentration of Quazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Quetiapine	The serum concentration of Quetiapine can be decreased when it is combined with Enzalutamide.	Approved
Quinacrine	The serum concentration of Quinacrine can be decreased when it is combined with Enzalutamide.	Approved
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Enzalutamide.	Approved
Quinine	The serum concentration of Quinine can be decreased when it is combined with Enzalutamide.	Approved
Rabeprazole	The serum concentration of Rabeprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Raloxifene	The serum concentration of Raloxifene can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ramelteon	The serum concentration of Ramelteon can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Enzalutamide.	Approved
Ranolazine	The serum concentration of Ranolazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Reboxetine	The serum concentration of Reboxetine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Regorafenib	The serum concentration of Regorafenib can be decreased when it is combined with Enzalutamide.	Approved
Repaglinide	The serum concentration of Repaglinide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Reserpine	The serum concentration of Reserpine can be increased when it is combined with Enzalutamide.	Approved
Retapamulin	The serum concentration of Retapamulin can be decreased when it is combined with Enzalutamide.	Approved
Rifabutin	The serum concentration of Enzalutamide can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Enzalutamide can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Enzalutamide can be decreased when it is combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Enzalutamide.	Approved
Rimexolone	The serum concentration of Rimexolone can be decreased when it is combined with Enzalutamide.	Approved
Rimonabant	The serum concentration of Rimonabant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be decreased when it is combined with Enzalutamide.	Approved
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ritonavir	The serum concentration of Enzalutamide can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide.	Approved
Rofecoxib	The serum concentration of Rofecoxib can be decreased when it is combined with Enzalutamide.	Investigational, Withdrawn
Roflumilast	The serum concentration of Roflumilast can be decreased when it is combined with Enzalutamide.	Approved
Rolapitant	The serum concentration of Rolapitant can be decreased when it is combined with Enzalutamide.	Approved
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ropinirole	The serum concentration of Ropinirole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ropivacaine	The serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide.	Approved
Rosiglitazone	The metabolism of Enzalutamide can be decreased when combined with Rosiglitazone.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be decreased when it is combined with Enzalutamide.	Approved
Rotigotine	The serum concentration of Rotigotine can be decreased when it is combined with Enzalutamide.	Approved
Roxithromycin	The serum concentration of Roxithromycin can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Ruxolitinib	The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.	Approved
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Enzalutamide.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be decreased when it is combined with Enzalutamide.	Approved
Saquinavir	The serum concentration of Saquinavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Enzalutamide.	Approved
Secobarbital	The serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital.	Approved, Vet Approved
Selegiline	The serum concentration of Selegiline can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Enzalutamide.	Approved
Seratrodast	The serum concentration of Seratrodast can be decreased when it is combined with Enzalutamide.	Approved
Sertindole	The serum concentration of Sertindole can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Sertraline	The serum concentration of Sertraline can be decreased when it is combined with Enzalutamide.	Approved
Sevoflurane	The serum concentration of Sevoflurane can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Sibutramine	The serum concentration of Sibutramine can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The serum concentration of Sildenafil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Enzalutamide.	Approved
Siltuximab	The serum concentration of Enzalutamide can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Simeprevir can be decreased when it is combined with Enzalutamide.	Approved
Simvastatin	The serum concentration of Simvastatin can be decreased when it is combined with Enzalutamide.	Approved
Sirolimus	The serum concentration of Sirolimus can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Enzalutamide.	Approved
Solifenacin	The serum concentration of Solifenacin can be decreased when it is combined with Enzalutamide.	Approved
Sonidegib	The serum concentration of Sonidegib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Enzalutamide.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Enzalutamide.	Experimental
Spiramycin	The serum concentration of Spiramycin can be decreased when it is combined with Enzalutamide.	Approved
St. John's Wort	The serum concentration of Enzalutamide can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Enzalutamide can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sulfadiazine	The serum concentration of Sulfadiazine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Sulfamethoxazole	The serum concentration of Sulfamethoxazole can be decreased when it is combined with Enzalutamide.	Approved
Sulfinpyrazone	The serum concentration of Sulfinpyrazone can be decreased when it is combined with Enzalutamide.	Approved
Sulfisoxazole	The metabolism of Enzalutamide can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sunitinib	The serum concentration of Sunitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be decreased when it is combined with Enzalutamide.	Approved
Synthetic Conjugated Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enzalutamide.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Enzalutamide.	Approved
Tacrolimus	The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tadalafil	The serum concentration of Tadalafil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Enzalutamide.	Approved
Tamsulosin	The serum concentration of Tamsulosin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tasimelteon	The serum concentration of Tasimelteon can be decreased when it is combined with Enzalutamide.	Approved
Tasosartan	The serum concentration of Tasosartan can be decreased when it is combined with Enzalutamide.	Approved
Taurochenodeoxycholic acid	The serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Enzalutamide.	Experimental
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Enzalutamide.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Enzalutamide.	Approved
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Enzalutamide.	Withdrawn
Telithromycin	The serum concentration of Telithromycin can be decreased when it is combined with Enzalutamide.	Approved
Temazepam	The serum concentration of Temazepam can be decreased when it is combined with Enzalutamide.	Approved
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Enzalutamide.	Approved
Teniposide	The serum concentration of Teniposide can be decreased when it is combined with Enzalutamide.	Approved
Terbinafine	The serum concentration of Terbinafine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Terfenadine	The serum concentration of Terfenadine can be decreased when it is combined with Enzalutamide.	Withdrawn
Teriflunomide	The metabolism of Enzalutamide can be decreased when combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Tesmilifene can be decreased when it is combined with Enzalutamide.	Investigational
Testosterone	The serum concentration of Testosterone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tetracycline	The serum concentration of Tetracycline can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Enzalutamide.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Enzalutamide.	Withdrawn
Thiotepa	The serum concentration of Thiotepa can be decreased when it is combined with Enzalutamide.	Approved
Tiagabine	The serum concentration of Tiagabine can be decreased when it is combined with Enzalutamide.	Approved
Ticagrelor	The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Enzalutamide resulting in a loss in efficacy.	Approved
Ticlopidine	The serum concentration of Ticlopidine can be decreased when it is combined with Enzalutamide.	Approved
Timolol	The serum concentration of Timolol can be increased when it is combined with Enzalutamide.	Approved
Tinidazole	The serum concentration of Tinidazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tiotropium	The serum concentration of Tiotropium can be decreased when it is combined with Enzalutamide.	Approved
Tipranavir	The serum concentration of Tipranavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tixocortol	The serum concentration of Tixocortol can be decreased when it is combined with Enzalutamide.	Approved
Tocilizumab	The serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	The serum concentration of Tofacitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tolterodine	The serum concentration of Tolterodine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Enzalutamide.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Enzalutamide.	Approved, Investigational
Toremifene	The serum concentration of Toremifene can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tramadol	The serum concentration of Tramadol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Enzalutamide.	Approved
Trazodone	The serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tretinoin	The serum concentration of Tretinoin can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Nutraceutical
Triamcinolone	The serum concentration of Triamcinolone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be decreased when it is combined with Enzalutamide.	Approved
Trimethadione	The serum concentration of Trimethadione can be decreased when it is combined with Enzalutamide.	Approved
Trimethoprim	The serum concentration of Trimethoprim can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Trimipramine	The serum concentration of Trimipramine can be decreased when it is combined with Enzalutamide.	Approved
Troglitazone	The serum concentration of Troglitazone can be decreased when it is combined with Enzalutamide.	Withdrawn
Udenafil	The serum concentration of Udenafil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Enzalutamide.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Enzalutamide.	Approved
Valdecoxib	The serum concentration of Valdecoxib can be decreased when it is combined with Enzalutamide.	Investigational, Withdrawn
Vandetanib	The serum concentration of Vandetanib can be decreased when it is combined with Enzalutamide.	Approved
Vanoxerine	The serum concentration of Vanoxerine can be decreased when it is combined with Enzalutamide.	Investigational
Vardenafil	The serum concentration of Vardenafil can be decreased when it is combined with Enzalutamide.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Enzalutamide.	Approved
Vemurafenib	The serum concentration of Vemurafenib can be decreased when it is combined with Enzalutamide.	Approved
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Enzalutamide.	Approved
Venlafaxine	The serum concentration of Venlafaxine can be decreased when it is combined with Enzalutamide.	Approved
Verapamil	The serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.	Approved
Vicriviroc	The serum concentration of Vicriviroc can be decreased when it is combined with Enzalutamide.	Investigational
Vilanterol	The serum concentration of Vilanterol can be decreased when it is combined with Enzalutamide.	Approved
Vilazodone	The serum concentration of Vilazodone can be decreased when it is combined with Enzalutamide.	Approved
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Enzalutamide.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be decreased when it is combined with Enzalutamide.	Approved
Vinorelbine	The serum concentration of Vinorelbine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Enzalutamide.	Approved
Vorapaxar	The serum concentration of Vorapaxar can be decreased when it is combined with Enzalutamide.	Approved
Voriconazole	The serum concentration of Voriconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vortioxetine	The serum concentration of Vortioxetine can be decreased when it is combined with Enzalutamide.	Approved
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Enzalutamide.	Approved
Yohimbine	The serum concentration of Yohimbine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Zafirlukast	The serum concentration of Zafirlukast can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Zalcitabine	The serum concentration of Zalcitabine can be decreased when it is combined with Enzalutamide.	Approved
Zaleplon	The serum concentration of Zaleplon can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Enzalutamide.	Approved
Zileuton	The serum concentration of Zileuton can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Ziprasidone	The serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide.	Approved
Zolpidem	The serum concentration of Zolpidem can be decreased when it is combined with Enzalutamide.	Approved
Zomepirac	The serum concentration of Zomepirac can be decreased when it is combined with Enzalutamide.	Withdrawn
Zonisamide	The serum concentration of Zonisamide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be decreased when it is combined with Enzalutamide.	Approved
Zuclopenthixol	The serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC: NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22. [PubMed:23699654 ]

External Links

Resource	Link
KEGG Drug	D10218
PubChem Compound	15951529
PubChem Substance	175427141
ChemSpider	13093347
BindingDB	50425732
ChEBI	68534
ChEMBL	CHEMBL1082407
Drug Product Database	22083
RxList	http://www.rxlist.com/xtandi-drug.htm
Drugs.com	http://www.drugs.com/cdi/enzalutamide.html
Wikipedia	Enzalutamide

ATC Codes

L02BB04 — Enzalutamide

AHFS Codes

10:00

PDB Entries

Not Available

FDA label

Download (393 KB)

MSDS

Download (89.7 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Not Yet Recruiting	Treatment	Clear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer	1
1	Active Not Recruiting	Treatment	Adenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer	1
1	Active Not Recruiting	Treatment	Bladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer	1
1	Active Not Recruiting	Treatment	Cancer, Breast	1
1	Active Not Recruiting	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
1	Active Not Recruiting	Treatment	Hormone Refractory Prostate Cancer / Prostate Cancer	1
1	Active Not Recruiting	Treatment	Malignant Neoplasm of Pancreas	1
1	Active Not Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
1	Active Not Recruiting	Treatment	Neoplasms / Solid Cancers	1
1	Active Not Recruiting	Treatment	Prostate Cancer	2
1	Completed	Not Available	Drug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics	1
1	Completed	Not Available	Healthy Volunteers / Kidney Diseases / Pharmacokinetics of MDV3100	1
1	Completed	Basic Science	Castration Resistant Prostate Cancer (CRPC) / Healthy Volunteers / MDV3100 / Relative Bioavailability	1
1	Completed	Basic Science	Drug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics of Enzalutamide	1
1	Completed	Basic Science	Healthy Volunteers / Pharmacokinetics of MDV3100	1
1	Completed	Basic Science	Normal Hepatic Function / Severe Hepatic Impairment	1
1	Completed	Basic Science	Pharmacokinetics of Caffeine / Pharmacokinetics of Dextromethorphan / Prostate Cancer	1
1	Completed	Basic Science	Pharmacokinetics of Enzalutamide / Prostate Cancer	1
1	Completed	Treatment	Castration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV3100	1
1	Not Yet Recruiting	Treatment	Malignant Neoplasm of Breast	1
1	Not Yet Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
1	Recruiting	Treatment	Cancers	1
1	Recruiting	Treatment	Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma	1
1	Recruiting	Treatment	Castration Resistant Prostate Cancer (CRPC) / Prostate Cancer	1
1	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	1
1	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer / Prostatic Neoplasms	1
1	Recruiting	Treatment	Prostate Cancer	1
1	Recruiting	Treatment	Prostatic Neoplasms, Castration-Resistant	1
1	Recruiting	Treatment	Tumors, Solid	1
1	Withdrawn	Treatment	Cancers	1
1, 2	Completed	Treatment	Castration Resistant Prostate Cancer (CRPC) / Prostate Cancer / Prostate Neoplasms	1
1, 2	Not Yet Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Estrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Progesterone Receptor Positive / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma	1
1, 2	Recruiting	Treatment	Hepatocellular,Carcinoma	1
1, 2	Recruiting	Treatment	Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Metastatic Castrate-Resistant Prostate Cancer	1
2	Active Not Recruiting	Basic Science	Metastatic Hormone Refractory Prostate Cancer	1
2	Active Not Recruiting	Other	Metastatic Castration Resistant Prostate Cancer	1
2	Active Not Recruiting	Treatment	Adenocarcinoma of the Prostate	1
2	Active Not Recruiting	Treatment	Adenocarcinoma, Prostate / High Risk Prostate Cancer / Prostate Cancer	1
2	Active Not Recruiting	Treatment	Advanced Breast Cancer / HER2 Amplified / Human Epidermal Growth Factor Receptor 2 (HER2)	1
2	Active Not Recruiting	Treatment	Advanced Hepatocellular Carcinoma	1
2	Active Not Recruiting	Treatment	Advanced, Androgen Receptor Positive Triple Negative Breast Cancer	1
2	Active Not Recruiting	Treatment	Cancer, Breast	1
2	Active Not Recruiting	Treatment	Castration Resistant Prostate Cancer (CRPC) / Prostate Carcinoma Metastatic to the Bone	1
2	Active Not Recruiting	Treatment	Hormone-Refractory Prostate Cancer	1
2	Active Not Recruiting	Treatment	Intermediate Risk Prostate Cancer	1
2	Active Not Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	1
2	Active Not Recruiting	Treatment	Prostate Cancer	10
2	Active Not Recruiting	Treatment	Prostate Carcinoma Metastatic to the Bone	1
2	Active Not Recruiting	Treatment	Prostatic Neoplasms	2
2	Completed	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
2	Completed	Treatment	Castration-Resistant Prostate Cancer (CRPC) / Prostate Cancer	1
2	Completed	Treatment	Metastatic Progressive Castration-resistant Prostate Cancer	1
2	Completed	Treatment	Prostate Cancer	3
2	Not Yet Recruiting	Treatment	Cancer, Breast	1
2	Not Yet Recruiting	Treatment	Prostate Cancer	2
2	Recruiting	Prevention	Bladder Cancers	1
2	Recruiting	Supportive Care	Adenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer	1
2	Recruiting	Treatment	Adenocarcinoma of the Prostate	2
2	Recruiting	Treatment	Adenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer	1
2	Recruiting	Treatment	Adenocarcinoma, Prostate / Prostate Cancer	1
2	Recruiting	Treatment	Advanced Epithelial Ovarian / Fallopian Tubes / Primary Peritoneal Carcinoma / Recurrent Epithelial Ovarian	1
2	Recruiting	Treatment	Cancer of the PROSTATE / Prostate Cancer	1
2	Recruiting	Treatment	Cancer, Breast	2
2	Recruiting	Treatment	Cancer, Breast / Early Stage / Triple Negative Breast Cancer (TNBC)	1
2	Recruiting	Treatment	Castration Resistant Metastatic Prostate Cancer	1
2	Recruiting	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
2	Recruiting	Treatment	Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Cancer	1
2	Recruiting	Treatment	Endometrial Cancers	1
2	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
2	Recruiting	Treatment	Metastatic Castration-Resistant Prostatic Cancer	1
2	Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer	3
2	Recruiting	Treatment	Non-metastatic, Hormone naïve Prostate Cancer	1
2	Recruiting	Treatment	Pelvic Nodal / Prostatic Neoplasms	1
2	Recruiting	Treatment	Primary Breast Cancer AR+ve TNBN / Primary Breast Cancer ER+ve	1
2	Recruiting	Treatment	Prostate Cancer	7
2	Recruiting	Treatment	Prostatic Neoplasms	1
2	Recruiting	Treatment	Salivary Cancer	1
2	Terminated	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
2	Withdrawn	Treatment	Localized Prostate Cancer / Prostate Cancer	1
2	Withdrawn	Treatment	Metastatic Castration Resistant Prostate Cancer	1
2, 3	Recruiting	Treatment	Castration-resistant Prostate Cancer Patients With Oligometastases	1
2, 3	Recruiting	Treatment	Prostate Cancer	1
3	Active Not Recruiting	Treatment	Adenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer	1
3	Active Not Recruiting	Treatment	Cancer of the PROSTATE / Nonmetastatic Castration-Resistant Prostate Cancer / Prostate Cancer	1
3	Active Not Recruiting	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
3	Active Not Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	1
3	Active Not Recruiting	Treatment	Progressive Metastatic Prostate Cancer	1
3	Active Not Recruiting	Treatment	Prostate Cancer	1
3	Active Not Recruiting	Treatment	Prostatic Neoplasms	1
3	Recruiting	Treatment	Cancer of the PROSTATE / Hormone Sensitive Prostate Cancer / Prostate Cancer	1
3	Recruiting	Treatment	Cancer, Breast	1
3	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	1
3	Recruiting	Treatment	Metastatic Hormone Sensitive Prostate Cancer	1
3	Recruiting	Treatment	Prostate Cancer	1
3	Recruiting	Treatment	Prostatic Neoplasms	1
3	Terminated	Treatment	Prostate Cancer	1
4	Active Not Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	1
4	Active Not Recruiting	Treatment	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
4	Active Not Recruiting	Treatment	Prostate Cancer	1
4	Recruiting	Supportive Care	Castration-Resistant Prostatic Cancer / Hormone-Refractory Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
4	Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
4	Recruiting	Treatment	Prostate Cancer	1
4	Terminated	Treatment	Metastatic Castration Resistant Prostate Cancer	1
Not Available	Active Not Recruiting	Not Available	Castration-Resistant Prostate Cancer (CRPC)	1
Not Available	Active Not Recruiting	Not Available	Metastatic Castration Resistant Prostate Cancer	1
Not Available	Approved for Marketing	Not Available	Metastatic Castration Resistant Prostate Cancer	1
Not Available	Recruiting	Not Available	Adenocarcinoma, Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
Not Available	Recruiting	Not Available	Castration resistant / Enzalutamide / Prostate Cancer	1
Not Available	Recruiting	Not Available	Prostate Cancer	1
Not Available	Recruiting	Treatment	Adenocarcinoma of the Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma in the Soft Tissue / Metastatic Prostatic Adenocarcinoma / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Cancer / Recurrent Prostate Carcinoma / Stage III Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Cancer	1
Not Available	Recruiting	Treatment	Adenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Stage IV Prostate Cancer	1
Not Available	Recruiting	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
Not Available	Recruiting	Treatment	Prostate Cancer	1
Not Available	Recruiting	Treatment	Recurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma	1
Not Available	Terminated	Treatment	Prostate Cancer	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Capsule	Oral	40 mg
Capsule	Oral	40 mg/1

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US8183274	No	2006-05-15	2026-05-15	US
US9126941	No	2006-05-15	2026-05-15	US
US7709517	No	2007-08-13	2027-08-13	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Insoluble	FDA label

Predicted Properties

Property	Value	Source
Water Solubility	0.00136 mg/mL	ALOGPS
logP	3.75	ALOGPS
logP	4.16	ChemAxon
logS	-5.5	ALOGPS
pKa (Strongest Acidic)	13.05	ChemAxon
pKa (Strongest Basic)	-1.7	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	76.44 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	113.48 m³·mol^-1	ChemAxon
Polarizability	42.71 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9356
Blood Brain Barrier	+	0.8514
Caco-2 permeable	+	0.5219
P-glycoprotein substrate	Non-substrate	0.7609
P-glycoprotein inhibitor I	Inhibitor	0.6464
P-glycoprotein inhibitor II	Inhibitor	0.5693
Renal organic cation transporter	Non-inhibitor	0.899
CYP450 2C9 substrate	Non-substrate	0.7447
CYP450 2D6 substrate	Non-substrate	0.8061
CYP450 3A4 substrate	Substrate	0.5589
CYP450 1A2 substrate	Non-inhibitor	0.5613
CYP450 2C9 inhibitor	Inhibitor	0.7126
CYP450 2D6 inhibitor	Non-inhibitor	0.9148
CYP450 2C19 inhibitor	Inhibitor	0.6882
CYP450 3A4 inhibitor	Inhibitor	0.6184
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.6711
Ames test	Non AMES toxic	0.683
Carcinogenicity	Non-carcinogens	0.7232
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.4319 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9911
hERG inhibition (predictor II)	Inhibitor	0.7079

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-014i-0321900000-b1c610c4a717fdea030e	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as phenylimidazolidines. These are polycyclic compounds containing an imidazoline substituted by a phenyl group.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Azolidines

Direct Parent

Phenylimidazolidines

Alternative Parents

Trifluoromethylbenzenes / 2-halobenzoic acids and derivatives / Alpha amino acids and derivatives / N-phenylthioureas / Benzamides / Benzoyl derivatives / Benzonitriles / Fluorobenzenes / Aryl fluorides / Imidazolidinones

Substituents

Phenylimidazolidine / Alpha-amino acid or derivatives / Trifluoromethylbenzene / N-phenylthiourea / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Benzonitrile / Benzoyl

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

benzamides, nitrile, imidazolidinone, monofluorobenzenes, (trifluoromethyl)benzenes, thiocarbonyl compound (CHEBI:68534 )

Targets

Details

1. Androgen receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Zinc ion binding
Specific Function:: Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:: AR
Uniprot ID:: P10275
Uniprot Name:: Androgen receptor
Molecular Weight:: 98987.9 Da

Enzymes

Details

1. Cytochrome P450 2C8

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:: CYP2C8
Uniprot ID:: P10632
Uniprot Name:: Cytochrome P450 2C8
Molecular Weight:: 55824.275 Da

Details

2. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinducer

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Uniprot Name:: Cytochrome P450 3A4
Molecular Weight:: 57342.67 Da

Details

3. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:: CYP2C9
Uniprot ID:: P11712
Uniprot Name:: Cytochrome P450 2C9
Molecular Weight:: 55627.365 Da

Details

4. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Uniprot Name:: Cytochrome P450 2C19
Molecular Weight:: 55930.545 Da

Details

5. Cytochrome P450 2B6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:: CYP2B6
Uniprot ID:: P20813
Uniprot Name:: Cytochrome P450 2B6
Molecular Weight:: 56277.81 Da

Details

6. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Uniprot Name:: Cytochrome P450 2D6
Molecular Weight:: 55768.94 Da

Details

7. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A5
Uniprot ID:: P20815
Uniprot Name:: Cytochrome P450 3A5
Molecular Weight:: 57108.065 Da

Carriers

Details

1. Serum albumin

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Toxic substance binding
Specific Function:: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:: ALB
Uniprot ID:: P02768
Uniprot Name:: Serum albumin
Molecular Weight:: 69365.94 Da

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

Drug created on June 04, 2013 23:12 / Updated on September 01, 2017 11:59

Structure for DB08899 (Enzalutamide)

Targets

Enzymes

Carriers

Transporters